![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
Through the divestment, Enanta will sale a Portion of Global Royalties on MAVYRET® (U.S.)/MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir) to OMERS Life Sciences. The net sale proceeds will be used to fund the continuing clinical development of virology pipeline.
Lead Product(s): Glecaprevir,Pibrentasvir
Therapeutic Area: Infections and Infectious Diseases Product Name: Mavyret
Highest Development Status: Phase IV Product Type: Small molecule
Partner/Sponsor/Collaborator: OMERS Life Sciences
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Divestment April 25, 2023